Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0777 in Generalized Anxiety Disorder
NCT00543920Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2002
- Primary completion
- Feb 2003
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in generalized anxiety disorder (GAD) comparing MK-0777 with Placebo (2 arms). Primary endpoint: Hamilton Anxiety Rating Scale at 4 weeks. Started Aug 2002; status: completed.
02
Drugs
tpa-023
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00543920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00543920.